March 13, 2025
Purdue University researchers in the College of Pharmacy and College of Science have received $124,984 from the Trask Innovation Fund to develop Purdue-owned intellectual property for commercial use.
Purdue Innovates funds advances in ag biotechnology, cancer treatments and fiber optics
March 12, 2025
Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25. The study will provide safety and efficacy data gathered from otherwise healthy participants infected with influenza then later treated with EV25.
Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza
March 12, 2025
Purdue University experts in the College of Science and Rosen Center for Advanced Computing have launched Molecular Intelligence, a software company whose solutions help researchers determine the 3D structures of biomolecules imaged with cryogenic-electron microscopy (cryo-EM).
Software startup Molecular Intelligence improves structuring molecules from cryo-EM image data
February 20, 2025
Company to commercialize PanCystPro, including establishing an early access program and completing a clinical utility trial in 2025
Amplified Sciences earns CLIA certification for its first test to assess pancreatic cancer risk
September 15, 2023
A Purdue researcher is taking a giant leap forward in the fight against drug-resistant strains of malaria in developing countries. Open Philanthropy has awarded $1.38 million to Philip Low to further validate a drug therapy that he and his colleagues have previously shown to successfully treat the disease. Low (rhymes with “now”) is Purdue University’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry in the College of Science.
Purdue researcher awarded $1.3 million for malaria drug trials in Southeast Asia and Africa
September 11, 2023
A Purdue University research group led by biochemistry professor W. Andy Tao collaborated with Tymora Analytical Operations, The Michael J. Fox Foundation for Parkinson's Research and Columbia University for a study that found a non-invasive way to potentially detect Parkinson’s disease in a patient’s urine.
Purdue research: Liquid biopsy method may reveal signs of Parkinson’s disease in urine samples
September 5, 2023
Purdue University’s novel use of an artificial intelligence model has revealed that biological pathways leading to cancer in dogs and humans are more similar than previously known. The study demonstrates enhanced value in studying naturally occurring cancer in dogs to learn more about how to defeat cancer in humans.
Purdue pioneers AI application and database to advance cancer genetics research
September 5, 2023
A new cancer therapy developed by Purdue University researchers attacks tumors by tricking cancer cells into absorbing a snippet of RNA that naturally blocks cell division. As reported Monday (Sept. 4) in Oncogene, tumors treated with the new therapy did not increase in size over the course of a 21-day study, while untreated tumors tripled in size over the same time period.
First-in-class targeted microRNA therapy slows cancer tumor growth
August 30, 2023
WEST LAFAYETTE, Ind. – How much time elapses between a blow to the head and the start of damage associated with Alzheimer’s disease? A device that makes it possible to track the effects of concussive force on a functioning cluster of brain cells suggests the answer is in hours. The “traumatic brain injury (TBI) on a chip” being developed at Purdue University opens a window into a cause and effect that announces itself with the passage of decades but is exceedingly difficult to trace back to its origins.
Purdue research could help lead to proper treatments against long-term effects soon after head trauma
July 14, 2023
Purdue University researcher V. Jo Davisson and CEO Diana Caldwell are the founders of Amplified Sciences, a clinical-stage life sciences diagnostic company that focuses on accurately detecting and categorically assessing the risks of debilitating diseases. The National Cancer Institute has awarded Amplified Sciences a grant of approximately $400,000 to develop a test to determine if pancreatic cysts are benign or potentially malignant.
Amplified Sciences receives $400,000 NCI grant to improve early detection of pancreatic cancer
